2 Ways That Valeant Pharmaceuticals Intl Inc. Shares Could Get Crushed

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has some big problems on its hands.

The Motley Fool

There is a sweet bit of irony in the troubles facing Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). Its stock went into a slide last week after short-seller Andrew Left suggested the company was using a complex structure to “stuff the channel” (i.e. report false revenue to a company under its control). His conclusion now appears to be wrong; there is no longer reason to believe that Valeant is inflating revenue.

Yet Valeant’s business practices have raised plenty of other concerns, which is why the company’s share price hasn’t recovered. In fact, there are really two ways that Valeant’s shares could plummet. We take a look below.

The issues

Valeant’s troubles revolve around Philidor, a specialty pharmacy that seems to be under Valeant’s control.

According to numerous reports, Philidor has used some suspect tactics to boost sales for Valeant. This includes aggressively providing refills, covering patients’ copay requirements, and shipping product through other pharmacies in its “network”.

These practices often lead to prescription sales that otherwise would not have taken place. Ultimately, that cost falls on health insurers, who must pay for these drugs. Some of Philidor’s methods may also be illegal.

Two big question marks

There are two major ways this could hurt Valeant, other than the damage currently being done to the company’s reputation.

First of all, Valeant could potentially be held liable for Philidor’s actions. Bronte Capital, one of the research outfits that has uncovered dirt on Valeant, suggests that Philidor is guilty of many counts of mail fraud. This carries a penalty of US$1 million per instance, and we shouldn’t “try to calculate the fine.”

Valeant claims that it is protected, since it doesn’t technically own Philidor. But according to an article in The Wall Street Journal, Valeant employees were installed at Philidor, and often went to great lengths to hide this relationship.

Secondly, and perhaps more importantly, health insurers may start cracking down on Valeant. After all, they are surely tired of paying for drugs that patients don’t really need, and they wouldn’t like Valeant’s deceptive practices either.

What this means for the stock

To be very clear, Valeant’s stock still has a long way to fall. The company has roughly US$30 billion of debt, and its stock price implies that more favourable acquisitions are on the way.

So, at this point, you should steer clear of Valeant. This story won’t be over for a long time.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

ETF is short for exchange traded fund, a popular investment choice for Canadians
Stock Market

One ETF or Several? How to Keep Your Investments as Simple as Possible

Here's how choosing the right mix of ETFs could help you simplify your investments while building long-term wealth.

Read more »

ETFs can contain investments such as stocks
Dividend Stocks

1 Top Dividend ETF to Buy to Generate Passive Income

Vanguard's VDY pays monthly with a 0.22% MER and a 3% yield. See what $20,000 could earn, the bank and…

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

2 of the Best ETFs to Buy Now

Looking for the best ETFs to buy now? Explore how XEQT offers global stock exposure while ZAG adds Canadian bonds…

Read more »

groceries get more expensive as inflation rises
Dividend Stocks

2 TSX Giants to Buy for Decades of Growth and Dividends

Royal Bank of Canada (TSX:RY) and another dividend giant worth buying up for decades.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

A TFSA-Worthy Dividend Stock Paying 5.1% Monthly

Choice Properties could be a great monthly dividend stock for TFSA investors seeking attractive passive income and long-term growth potential.

Read more »

Colored pins on calendar showing a month
Dividend Stocks

How to Turn $7,500 Into a Money-Making TFSA Portfolio

One global equity ETF and two high-yield TSX dividend stocks can turn a $7,500 TFSA into a money-making portfolio built…

Read more »

A person uses and AI chat bot
Tech Stocks

This Canadian Tech Stock Is a Steal, and I’m Telling New Investors to Buy It Right Now

A beaten-down share price, growing cloud business, and AI-focused initiatives make this Canadian tech stock attractive for new investors seeking…

Read more »

Child measures his height on wall. He is growing taller.
Stocks for Beginners

National Bank Stock: How Much Growth Am I Willing to Pay for?

National Bank’s growth is worth paying for up to a point. I’d work backwards from the share price before adding…

Read more »